دورية أكاديمية
Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II
| العنوان: | Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II |
|---|---|
| المؤلفون: | Mina Fathi-Kazerooni, Samrand Fattah-Ghazi, Maryam Darzi, Jalil Makarem, Reza Nasiri, Faeze Salahshour, Seyed Ali Dehghan-Manshadi, Somaieh Kazemnejad |
| المصدر: | Stem Cell Research & Therapy, Vol 13, Iss 1, Pp 1-15 (2022) |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine (General) LCC:Biochemistry |
| مصطلحات موضوعية: | COVID-19, Menstrual blood stromal cells, Secretome, GMP, New treatment, Medicine (General), R5-920, Biochemistry, QD415-436 |
| الوصف: | Abstract Background Cell-free Mesenchymal stromal cells (MSCs) have been considered due to their capacity to modulate the immune system and suppress cytokine storms caused by SARS-CoV-2. This prospective randomized double-blind placebo-controlled clinical trial aimed to assess the safety and efficacy of secretome derived from allogeneic menstrual blood stromal cells (MenSCs) as a treatment in patients with severe COVID-19. Methods Patients with severe COVID-19 were randomized (1:1) to either MenSC-derived secretome treatment or the control group. Subjects received five intravenous infusions of 5 mL secretome or the same volume of placebo for five days and were monitored for safety and efficacy for 28 days after treatment. Adverse events, laboratory parameters, duration of hospitalization, clinical symptom improvement, dynamic of O2 saturation, lymphocyte number, and serial chest imaging were analyzed. Results All safety endpoints were observed without adverse events after 72 h of secretome injection. Within 28 days after enrollment, 7 patients (50%) were intubated in the treated group versus 12 patients (80%) in the control group. Overall, 64% of patients had improved oxygen levels within 5 days of starting treatment (P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1757-6512 |
| Relation: | https://doaj.org/toc/1757-6512 |
| DOI: | 10.1186/s13287-022-02771-w |
| URL الوصول: | https://doaj.org/article/cf3e9fd3fd6d484cb84302452db14ae4 |
| رقم الأكسشن: | edsdoj.f3e9fd3fd6d484cb84302452db14ae4 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 17576512 |
|---|---|
| DOI: | 10.1186/s13287-022-02771-w |